[12] Patent
[11] Patent No.:GC0007793  
[45] Date of Publishing the Grant of the Patent: 31/May /2018                49/2018  
Number of the Decision to Grant the Patent:2018/127577
Date of the Decision to Grant the Patent:17/May/2018

[21] Application No.:GC 2013-23351

[22] Filing Date:19/1/2013

[30] Priority:

[33] State [32] Priority date [31] Priority No.

[72] Inventors:1- Herder, Martin،2- Mett, Ingo ،3- Ludanek, Gerhard،4- Schmidt, Joachim

[73] Owner: AstraZeneca AB, SE-151 85 , Sodertalje , Sweden

[74] Agent: Saba & Co. T.M.P




Int. Cl.: A61M15/00 (2006.01)

[56] Cited Documents:

-WO 2006106367 A1 (AVENTIS PHARMA LTD [GB] 12 OCTOBER 2006
-EP1616592 B9 (SOFOTEC GMBH &CO KG [DE]18 JANUARY 2006
-US 2006037612 A1 (HERDER MARTIN [DE] 23FEBRUARY 2006
Examiner: PH. Nada M. AlBehaiji

[57] Abstract: The invention relates to an inhalation device for powdered drugs to be received by a patient by an inhalation-caused air stream, comprising at least one powder reservoir, metering means for repeatedly metering a powder dose from the reservoir, a transportation mechanism for moving said metering means from a filling position for receiving a powder dose into an emptying position for releasing said powder dose into a powder channel, at least one activating device for manual operation by the patient, said activating device being operatively connected to said transportation mechanism such that upon operation a single powder dose is being metered, said activating device comprising a dosage key (5) acting on said transportation mechanism when pressed by the patient. The inhalation device further comprises an advancing mechanism for advancing a counter means each time the inhalation device has been activated by the patient so that a powder dose has been released into the powder channel. The counter means comprises a mechanical index coupled to a locking mechanism blocking the dosage key (5) and/or the activating device and/or the transportation mechanism after a predetermined number of metering cycles after detection of the index. Moreover, the locking mechanism includes a locking lever (7) for positive engagement with the dosage key (5) and/or the activating device and/or the transportation mechanism in the blocked condition. The inhalation device (1) is characterized in that the locking lever includes signaling means integrally formed therewith engaging the index after said predetermined number of metering cycles.(Figure 1)
No. of claims: 15     No. of figures: 20


Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.